Previous prospective studies highlighted aberrant immunoglobulin G (IgG) N-glycosylation as a risk factor for dementia [such as Alzheimer’s disease (AD) and vascular dementia (VaD)]. It is unclear whether this association is causal or explained by confounding or reverse causation.
Objective:
The aim is to examine the association of genetically predicted IgG N-glycosylation with dementia using 2-sample Mendelian randomization (MR).
Methods:
Independent genetic variants for IgG N-glycosylation traits were selected as instrument variables from published genome-wide association studies (GWAS) among individuals of European ancestry. We extracted their corresponding summary statistics from large-scale clinically diagnosed AD GWAS dataset and FinnGen biobank VaD GWAS dataset. The inverse variance weighted (IVW) was performed to calculate the effect estimates. Meanwhile, multiple sensitivity analyses were used to assess horizontal pleiotropy and outliers.
Results:
There were no associations of genetically predicted IgG N-glycosylation traits with the risk of AD and VaD using the IVW method (all Bonferroni corrected p > 0.0013). These estimates of four additional sensitivity analyses methods were consistent with the IVW estimates in terms of direction and magnitude. Additionally, the MR-PRESSO global test and the intercept of MR-Egger regression indicated no evidence of horizontal pleiotropy. Meanwhile, the heterogeneity test showed no significant heterogeneity using the Cochran Q statistic. The leave-one-out sensitivity analyses also did not detect any significant change.
Conclusion:
Our MR study did not support evidence for the hypothesis that IgG N-glycosylation level may be causally associated with the risk of dementia.
(2019) Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol18, 88–106.
2.
QiuC, KivipeltoM, von StraussE (2009) Epidemiology of Alzheimer’s disease: Occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci11, 111–128.
3.
IadecolaC (2013) The pathobiology of vascular dementia. Neuron80, 844–866.
4.
KingE, O’BrienJT, DonaghyP, MorrisC, BarnettN, OlsenK, Martin-RuizC, TaylorJP, ThomasAJ (2018) Peripheral inflammation in prodromal Alzheimer’s and Lewy body dementias. J Neurol Neurosurg Psychiatry89, 339–345.
5.
KoyamaA, O’BrienJ, WeuveJ, BlackerD, MettiAL, YaffeK (2013) The role of peripheral inflammatory markers in dementia and Alzheimer’s disease: A meta-analysis. J Gerontol A Biol Sci Med Sci68, 433–440.
6.
WoodH (2018) Dementia: Peripheral inflammation could be a prodromal indicator of dementia. Nat Rev Neurol14, 127.
7.
SkropetaD (2009) The effect of individual N-glycans on enzyme activity. Bioorg Med Chem17, 2645–2653.
8.
ArnoldJN, WormaldMR, SimRB, RuddPM, DwekRA (2007) The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol25, 21–50.
9.
MarekKW, VijayIK, MarthJD (1999) A recessive deletion in the GlcNAc-1-phosphotransferase gene results in peri-implantation embryonic lethality. Glycobiology9, 1263–1271.
10.
JaekenJ, MatthijsG (2007) Congenital disorders of glycosylation: A rapidly expanding disease family. Annu Rev Genomics Hum Genet8, 261–278.
11.
OhtsuboK, MarthJD (2006) Glycosylation in cellular mechanisms of health and disease. Cell126, 855–867.
12.
VidarssonG, DekkersG, RispensT (2014) IgG subclasses and allotypes: From structure to effector functions. Front Immunol5, 520.
13.
NovokmetM, LukićE, VuckovićF, THurićŽ, KeserT, RajslK, RemondiniD, CastellaniG, GasparovićH, GornikO, LaucG (2014) Changes in IgG and total plasma proteinglycomes in acute systemic inflammation. Sci Rep4, 4347.
14.
KanekoY, NimmerjahnF, RavetchJV (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science313, 670–673.
15.
AnthonyRM, RavetchJV (2010) A novel role for the IgG Fc glycan: The anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol30 Suppl 1, S9–14.
16.
NimmerjahnF, RavetchJV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol8, 34–47.
17.
FerraraC, StuartF, SondermannP, BrünkerP, UmañaP (2006) The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem281, 5032–5036.
18.
de JongSE, SelmanMH, AdegnikaAA, AmoahAS, van RietE, KruizeYC, RaynesJG, RodriguezA, BoakyeD, von MutiusE, KnulstAC, GenuneitJ, CooperPJ, HokkeCH, WuhrerM, YazdanbakhshM (2016) IgG1 Fc N-glycan galactosylation as a biomarker for immune activation. Sci Rep6, 28207.
19.
PlompR, RuhaakLR, UhHW, ReidingKR, SelmanM, Houwing-DuistermaatJJ, SlagboomPE, BeekmanM, WuhrerM (2017) Subclass-specific IgG glycosylation is associated with markers of inflammation and metabolic health. Sci Rep7, 12325.
20.
LundströmSL, YangH, LyutvinskiyY, RutishauserD, HerukkaSK, SoininenH, ZubarevRA (2014) Blood plasma IgG Fc glycans are significantly altered in Alzheimer’s disease and progressive mild cognitive impairment. J Alzheimers Dis38, 567–579.
21.
GizawST, OhashiT, TanakaM, HinouH, NishimuraS (2016) Glycoblotting method allows for rapid and efficient glycome profiling of human Alzheimer’s disease brain, serum and cerebrospinal fluid towards potential biomarker discovery. Biochim Biophys Acta1860, 1716–1727.
22.
LawlorDA, HarbordRM, SterneJA, TimpsonN, Davey SmithG (2008) Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology. Stat Med27, 1133–1163.
23.
DaviesNM, HoweLJ, BrumptonB, HavdahlA, EvansDM, Davey SmithG (2019) Within family Mendelian randomization studies. Hum Mol Genet28, R170–r179.
24.
HemaniG, ZhengJ, ElsworthB, WadeKH, HaberlandV, BairdD, LaurinC, BurgessS, BowdenJ, LangdonR, TanVY, YarmolinskyJ, ShihabHA, TimpsonNJ, EvansDM, ReltonC, MartinRM, Davey SmithG, GauntTR, HaycockPC (2018) The MR-Base platform supports systematic causal inference across the human phenome. Elife7, e34408.
25.
SkrivankovaVW, RichmondRC, WoolfBAR, YarmolinskyJ, DaviesNM, SwansonSA, VanderWeeleTJ, HigginsJPT, TimpsonNJ, DimouN, LangenbergC, GolubRM, LoderEW, GalloV, Tybjaerg-HansenA, Davey SmithG, EggerM, RichardsJB (2021) Strengthening the reporting of observational studies in epidemiology using mendelian randomization: The STROBE-MR statement. JAMA326, 1614–1621.
BurgessS, ButterworthA, ThompsonSG (2013) Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol37, 658–665.
30.
BurgessS, FoleyCN, ZuberV (2018) Inferring causal relationships between risk factors and outcomes from genome-wide association study data. Annu Rev Genomics Hum Genet19, 303–327.
31.
BurgessS, SmallDS, ThompsonSG (2017) A review of instrumental variable estimators for Mendelian randomization. Stat Methods Med Res26, 2333–2355.
32.
BowdenJ, Davey SmithG, HaycockPC, BurgessS (2016) Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol40, 304–314.
33.
VerbanckM, ChenCY, NealeB, DoR (2018) Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet50, 693–698.
34.
BowdenJ, Davey SmithG, BurgessS (2015) Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression. Int J Epidemiol44, 512–525.
35.
BurgessS, BowdenJ, FallT, IngelssonE, ThompsonSG (2017) Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants. Epidemiology28, 30–42.
36.
MaguireTM, GillianAM, O’MahonyD, CoughlanCM, DennihanA, BreenKC (1994) A decrease in serum sialyltransferase levels in Alzheimer’s disease. Neurobiol Aging15, 99–102.
SchoolingCM, LopezPM, YangZ, ZhaoJV, Au YeungSL, HuangJV (2020) Use of multivariable Mendelian randomization to address biases due to competing risk before recruitment. Front Genet11, 610852.
39.
LaucG, HuffmanJE, PucićM, ZgagaL, AdamczykB, MuzinićA, NovokmetM, PolasekO, GornikO, KristićJ, KeserT, VitartV, ScheijenB, UhHW, MolokhiaM, PatrickAL, McKeigueP, KolcićI, LukićIK, SwannO, vanLeeuwenFN, RuhaakLR, Houwing-DuistermaatJJ, SlagboomPE, BeekmanM, de CraenAJ, DeelderAM, ZengQ, WangW, HastieND, GyllenstenU, WilsonJF, WuhrerM, WrightAF, RuddPM, HaywardC, AulchenkoY, CampbellH, RudanI (2013) Loci associated with N-glycosylation ofhuman immunoglobulin G show pleiotropy with autoimmune diseases andhaematological cancers. PLoS Genet9, e1003225.
40.
YuX, WangY, KristicJ, DongJ, ChuX, GeS, WangH, FangH, GaoQ, LiuD, ZhaoZ, PengH, Pucic BakovicM, WuL, SongM, RudanI, CampbellH, LaucG, WangW (2016) Profiling IgG N-glycans as potential biomarker of chronological and biological ages: A community-based study in a Han Chinese population. Medicine (Baltimore)95, e4112.
41.
LabrecqueJA, SwansonSA (2019) Interpretation and potential biases of mendelian randomization estimates with time-varying exposures. Am J Epidemiol188, 231–238.
